Dakota Wealth Management Sells 21,441 Shares of Zoetis Inc. (NYSE:ZTS)

Dakota Wealth Management decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 24.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,541 shares of the company's stock after selling 21,441 shares during the quarter. Dakota Wealth Management's holdings in Zoetis were worth $10,791,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ZTS. Vanguard Group Inc. lifted its stake in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after acquiring an additional 120,158 shares during the period. Geode Capital Management LLC raised its holdings in Zoetis by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock worth $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Polen Capital Management LLC lifted its position in Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Wellington Management Group LLP boosted its stake in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Zoetis by 13.3% during the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after purchasing an additional 755,893 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.5%

NYSE:ZTS traded up $0.72 during trading hours on Monday, hitting $155.68. 1,986,473 shares of the company's stock traded hands, compared to its average volume of 3,011,381. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market cap of $69.31 billion, a P/E ratio of 27.95, a P/E/G ratio of 2.57 and a beta of 0.91. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The stock's fifty day moving average price is $161.32 and its two-hundred day moving average price is $161.82.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is currently 35.91%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ZTS shares. Piper Sandler upped their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $212.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.